Trump Cannabis Policy 2025: Federal Rescheduling and Industry Impact

Executive Summary

President Donald Trump's cannabis policy stance in 2025 has evolved from campaign-trail ambiguity to concrete regulatory action, triggering significant market volatility and reshaping the multi-billion dollar U.S. cannabis industry. After decades of federal prohibition under the Controlled Substances Act, Trump's administration signaled a potential shift toward rescheduling cannabis from Schedule I to Schedule III, a move that would fundamentally alter tax treatment, research access, and banking relationships for state-licensed operators. The policy shift reached Wall Street in June 2026, according to The Washington Post, as investors recalibrated valuations for multi-state operators facing both opportunity and uncertainty. Trump's approach combines deference to state-level legalization programs with selective federal enforcement priorities, creating a complex regulatory landscape that affects approximately 40 states with medical or adult-use programs, over 15,000 licensed businesses, and an estimated $30 billion annual market. The administration's actions represent the most significant federal cannabis policy development since the 2013 Cole Memorandum, with implications extending from Section 280E tax burdens to interstate commerce restrictions and international treaty obligations.

Why This Matters

Trump's cannabis policy decisions directly impact 300 million Americans living in states with legal cannabis programs, $100 billion in cumulative industry investment, and the criminal justice outcomes for thousands arrested annually under federal prohibition. The stakeholder universe spans multiple dimensions. State-licensed cannabis operators, including publicly traded multi-state operators like Curaleaf, Trulieve, Green Thumb Industries, and Verano, collectively employ over 400,000 workers and generated approximately $30 billion in retail sales during 2024. These businesses currently operate under effective federal tax rates exceeding 70 percent due to Internal Revenue Code Section 280E, which prohibits standard business deductions for entities trafficking in Schedule I or II controlled substances. Rescheduling to Schedule III would eliminate this tax penalty, potentially freeing $2-3 billion annually in operator cash flow. Medical patients represent another critical constituency. An estimated 6 million Americans hold state-issued medical cannabis cards, using cannabis to treat conditions ranging from chronic pain and PTSD to epilepsy and cancer-related symptoms. Federal rescheduling would expand research opportunities under the FDA framework, potentially leading to FDA-approved cannabis medications and insurance coverage. Veterans, who face federal prohibition despite state-level access, would gain clearer pathways to treatment through the Department of Veterans Affairs. Financial institutions remain constrained by federal prohibition. The Bank Secrecy Act and anti-money laundering regulations create compliance risks for banks serving cannabis clients, forcing approximately 60 percent of cannabis transactions into cash-only operations. Trump administration policy on enforcement priorities directly determines whether regional banks expand cannabis banking services or maintain restrictive policies. Criminal justice implications extend beyond current arrests. While state-level legalization has reduced cannabis arrests from 850,000 annually in 2010 to approximately 350,000 in 2024, federal prosecution continues for cultivation and distribution offenses. The administration's enforcement priorities determine whether federal prosecutors pursue cases in states with legal markets, affecting sentencing outcomes under mandatory minimum statutes.

Background and History

Trump's 2025 cannabis policy emerged from a 50-year federal prohibition framework established by the Controlled Substances Act of 1970, which classified cannabis as Schedule I alongside heroin, defining it as having no accepted medical use and high abuse potential.

The Controlled Substances Act Foundation (1970-2012)

Congress enacted the Controlled Substances Act as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, codified at 21 U.S.C. § 801 et seq. The statute established five schedules of controlled substances, with Schedule I reserved for drugs meeting three criteria: high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. The Drug Enforcement Administration, operating under the Department of Justice, received authority to enforce scheduling decisions. Cannabis remained in Schedule I despite the 1972 Shafer Commission recommendation for decriminalization. The classification created a federal-state tension that intensified after California voters approved Proposition 215 in 1996, establishing the nation's first medical cannabis program. By 2012, 18 states had enacted medical cannabis laws, and Colorado and Washington voters approved adult-use legalization in November 2012, creating direct conflicts with federal prohibition.

Obama Administration Guidance (2013-2017)

The Obama administration addressed the federal-state conflict through prosecutorial discretion rather than statutory reform. Deputy Attorney General James Cole issued a memorandum on August 29, 2013, establishing eight enforcement priorities for federal prosecutors in states with legal cannabis frameworks. The Cole Memorandum directed U.S. Attorneys to focus resources on preventing distribution to minors, revenue diversion to criminal enterprises, interstate diversion, violence, drugged driving, cultivation on public lands, possession on federal property, and possession or use on federal property. The guidance provided operational certainty for state-licensed businesses while maintaining federal prohibition. The Treasury Department's Financial Crimes Enforcement Network issued corresponding guidance on February 14, 2014, establishing Bank Secrecy Act compliance expectations for financial institutions serving cannabis clients. The Obama administration also implemented the Rohrabacher-Farr Amendment, an annual appropriations rider prohibiting the Department of Justice from using funds to prevent states from implementing medical cannabis laws.

Trump First Term (2017-2021)

Trump's first-term cannabis policy combined contradictory signals. Attorney General Jeff Sessions rescinded the Cole Memorandum on January 4, 2018, through a one-page memo directing U.S. Attorneys to follow established principles governing federal prosecution decisions. The Sessions memo eliminated formal enforcement priorities, creating uncertainty for state-licensed operators and triggering a 30 percent decline in cannabis equity valuations over the subsequent quarter. Despite Sessions' hardline approach, Trump personally expressed support for state-level legalization. During the 2016 campaign, Trump told a Colorado television station that legalization should be "up to the states." In June 2018, Trump told Senator Cory Gardner he would support legislative protections for state cannabis programs, leading to the introduction of the STATES Act, which would have exempted state-compliant cannabis activity from the Controlled Substances Act. The legislation never received a floor vote. Trump's first administration took no action on cannabis rescheduling petitions pending before the DEA. The administration maintained Section 280E enforcement, continued federal prosecution of cultivation operations in legal states, and opposed banking reform legislation. However, Trump signed the 2018 Farm Bill on December 20, 2018, legalizing hemp production and removing hemp-derived cannabidiol from Schedule I, creating the legal framework for the CBD market.

Biden Administration Rescheduling Initiative (2021-2024)

President Joe Biden initiated the most significant federal cannabis policy review in decades on October 6, 2022, directing Health and Human Services Secretary Xavier Becerra and Attorney General Merrick Garland to review cannabis scheduling. The directive followed Biden's announcement of mass pardons for federal simple possession convictions, affecting approximately 6,500 individuals. HHS completed its review in August 2023, recommending rescheduling cannabis to Schedule III based on an eight-factor analysis required by 21 U.S.C. § 811(c). The recommendation, transmitted to the DEA, concluded that cannabis has accepted medical use, lower abuse potential than Schedule I or II substances, and moderate to low physical dependence liability. The DEA published a Notice of Proposed Rulemaking on May 16, 2024, initiating a formal rescheduling process including public comment periods and administrative law judge hearings. The Biden rescheduling initiative remained pending when Trump won the November 2024 presidential election, creating uncertainty about whether the incoming administration would continue or abandon the process.

Trump 2024 Campaign Positioning

Trump's 2024 campaign marked a notable shift toward explicit cannabis reform support. On September 3, 2024, Trump posted on Truth Social: "As I have previously stated, I believe it is time to end needless arrests and incarcerations of adults for small amounts of marijuana for personal use. We must also implement smart regulations, while providing access for adults, to safe, tested product." Trump explicitly endorsed Florida's Amendment 3 adult-use legalization ballot initiative, breaking with Florida Governor Ron DeSantis, who opposed the measure. Trump's campaign platform included support for rescheduling, state-level legalization rights, and banking reform. The positioning aligned Trump with growing Republican support for cannabis reform, including endorsements from Representatives Nancy Mace and Dave Joyce, who introduced the States Reform Act in 2022. However, Trump provided limited specifics on implementation timelines or regulatory frameworks, leaving industry stakeholders uncertain about concrete policy outcomes.

Key Players

Drug Enforcement Administration

The DEA holds statutory authority under 21 U.S.C. § 811 to schedule controlled substances based on eight factors including abuse potential, scientific evidence, history and current pattern of abuse, scope and significance of abuse, and risk to public health. DEA Administrator Anne Milgram oversaw the agency's response to the Biden-initiated rescheduling recommendation. The DEA's Notice of Proposed Rulemaking published in May 2024 initiated formal Administrative Procedure Act processes including public comment periods and administrative law judge hearings. Trump's appointment of a new DEA Administrator in January 2025 directly influenced whether the agency would finalize rescheduling or withdraw the proposal.

Department of Health and Human Services

HHS conducts the scientific and medical evaluation required for scheduling decisions under the Controlled Substances Act. The Food and Drug Administration, operating within HHS, completed the eight-factor analysis recommending Schedule III classification in August 2023. The recommendation represented the first time a federal health agency concluded that cannabis has accepted medical use in treatment in the United States, directly contradicting the Schedule I criteria. HHS Secretary Robert F. Kennedy Jr., appointed by Trump in January 2025, oversees FDA cannabis policy including approval pathways for cannabis-derived medications and research protocols.

Department of Justice

The DOJ sets federal prosecution priorities through U.S. Attorney offices in 94 federal districts. Attorney General Pam Bondi, confirmed in February 2025, determines whether federal prosecutors pursue cannabis cases in states with legal frameworks. The DOJ also oversees the Bureau of Alcohol, Tobacco, Firearms and Explosives, which enforces prohibitions on firearm possession by cannabis users under 18 U.S.C. § 922(g)(3). DOJ guidance documents, similar to the rescinded Cole Memorandum, provide operational certainty for state-licensed businesses and financial institutions.

Multi-State Operators

Publicly traded cannabis companies including Curaleaf Holdings, Green Thumb Industries, Trulieve Cannabis, Verano Holdings, Cresco Labs, and Ayr Wellness operate retail, cultivation, and manufacturing licenses across multiple states. These MSOs collectively hold over $15 billion in market capitalization and generated approximately $12 billion in combined revenue during 2024. The companies face effective tax rates exceeding 70 percent under Section 280E, limited access to institutional capital due to federal prohibition, and restrictions on interstate commerce. Rescheduling to Schedule III would eliminate Section 280E burdens, expand banking relationships, and potentially enable Nasdaq or NYSE uplisting from over-the-counter markets.

National Cannabis Industry Association

The NCIA represents over 1,500 cannabis businesses in federal and state policy advocacy. The organization supported the Biden rescheduling initiative while advocating for full descheduling and removal of cannabis from the Controlled Substances Act entirely. NCIA submitted detailed comments during the DEA's Notice of Proposed Rulemaking process, arguing that Schedule III classification fails to address interstate commerce restrictions, international treaty obligations, and continued criminal penalties for non-medical use.

Smart Approaches to Marijuana

SAM, founded by former Representative Patrick Kennedy, opposes cannabis legalization and rescheduling. The organization argues that cannabis poses public health risks including addiction, impaired driving, and youth access. SAM submitted comments opposing the DEA rescheduling proposal, citing concerns about normalization and commercialization. The organization advocates for maintaining Schedule I classification while expanding access to FDA-approved cannabis medications through traditional drug approval pathways.

Legal and Regulatory Framework

Cannabis policy operates within a complex federal statutory framework including the Controlled Substances Act, Internal Revenue Code Section 280E, the Bank Secrecy Act, and international treaty obligations under the 1961 Single Convention on Narcotic Drugs. The Controlled Substances Act establishes the foundation. Under 21 U.S.C. § 841(a)(1), manufacturing, distributing, or possessing with intent to distribute a controlled substance constitutes a federal felony. Penalties vary by substance schedule and quantity. For Schedule I cannabis, cultivation of 1,000 plants or more triggers a 10-year mandatory minimum sentence under 21 U.S.C. § 841(b)(1)(A)(vii). Rescheduling to Schedule III would reduce maximum penalties while maintaining federal prohibition for non-medical use. Section 280E of the Internal Revenue Code, enacted in 1982, prohibits businesses from deducting ordinary business expenses if they traffic in Schedule I or II controlled substances. The provision allows deduction of cost of goods sold but disallows deductions for rent, salaries, marketing, and other operating expenses. Cannabis businesses report effective federal tax rates of 70-90 percent compared to 21-30 percent for non-cannabis businesses. Rescheduling to Schedule III would eliminate Section 280E application, as the statute applies only to Schedule I and II substances. The Bank Secrecy Act, codified at 31 U.S.C. § 5311 et seq., requires financial institutions to file Suspicious Activity Reports for transactions involving proceeds of unlawful activity. Cannabis revenue constitutes proceeds of federal drug trafficking under current law, creating compliance obligations for banks serving cannabis clients. The Financial Crimes Enforcement Network's 2014 guidance established "marijuana-limited" and "marijuana priority" SAR categories, but many financial institutions decline cannabis clients due to compliance costs and regulatory uncertainty. Federal firearms prohibitions under 18 U.S.C. § 922(g)(3) bar unlawful users of controlled substances from possessing firearms. The Bureau of Alcohol, Tobacco, Firearms and Explosives issued guidance in 2011 clarifying that medical cannabis patients qualify as unlawful users under federal law. The Ninth Circuit upheld this interpretation in Wilson v. Lynch, 835 F.3d 1083 (9th Cir. 2016). Rescheduling would not eliminate the prohibition, as Schedule III substances remain controlled substances under federal law. International treaty obligations complicate federal policy reform. The United States is party to the 1961 Single Convention on Narcotic Drugs, which requires signatories to limit cannabis to medical and scientific purposes. The treaty permits parties to withdraw or seek amendments through United Nations processes. Uruguay and Canada legalized adult-use cannabis while remaining treaty parties, arguing that domestic legalization does not violate international obligations. The Trump administration's approach to treaty compliance remains unclear.

State-by-State Breakdown

As of January 2025, 24 states, two territories, and the District of Columbia have legalized adult-use cannabis, while 38 states have comprehensive medical cannabis programs, creating a patchwork of regulations that federal policy must navigate.

California

California operates the nation's largest cannabis market, with approximately $5.5 billion in annual legal sales. Voters approved Proposition 64 in November 2016, legalizing adult-use cannabis effective January 1, 2018. The state allows possession of up to one ounce of flower and eight grams of concentrate for adults 21 and older. California's regulatory framework, administered by the Department of Cannabis Control, includes cultivation, manufacturing, distribution, testing, and retail license types. The state imposes a 15 percent excise tax on retail sales plus local taxes reaching 10 percent in some jurisdictions. Federal rescheduling would not directly change California's regulatory structure but would improve operator profitability through Section 280E elimination.

New York

New York legalized adult-use cannabis through the Marijuana Regulation and Taxation Act, signed by Governor Andrew Cuomo on March 31, 2021. The state launched retail sales in December 2022, later than initially projected due to licensing delays and legal challenges. New York allows possession of up to three ounces of flower for adults 21 and older. The Office of Cannabis Management oversees licensing, with priority given to social equity applicants including individuals with prior cannabis convictions. New York imposes a 13 percent state tax plus 4 percent local tax on retail sales. The state's market reached approximately $1.2 billion in legal sales during 2024, competing with an estimated $3 billion illicit market.

Florida

Florida operates a medical-only program established by the Compassionate Medical Cannabis Act of 2014 and expanded through subsequent legislation. Approximately 800,000 Floridians hold medical cannabis cards, making it the nation's third-largest medical market. Patients with qualifying conditions including cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, and multiple sclerosis may possess up to 2.5 ounces of flower in a 35-day period. Amendment 3, the adult-use legalization ballot initiative endorsed by Trump, failed to achieve the 60 percent supermajority required for constitutional amendments in November 2024, receiving 58.4 percent support. Florida remains medical-only, with federal rescheduling potentially expanding research opportunities for the state's 22 licensed medical marijuana treatment centers.

Texas

Texas maintains one of the nation's most restrictive medical cannabis programs, limited to patients with epilepsy, seizure disorders, multiple sclerosis, spasticity, ALS, autism, terminal cancer, and incurable neurodegenerative diseases. The Texas Compassionate Use Program, established in 2015 and expanded in 2019 and 2021, restricts THC content to one percent by weight. Approximately 75,000 Texans participate in the program. Possession of any amount of cannabis outside the medical program remains a criminal offense, with penalties ranging from Class B misdemeanors for under two ounces to felonies for larger quantities. Federal rescheduling would not directly change Texas law but could influence legislative debates on program expansion.

Ohio

Ohio voters approved Issue 2 in November 2023, legalizing adult-use cannabis effective December 7, 2023. The state allows possession of up to 2.5 ounces of flower and 15 grams of concentrate for adults 21 and older. Ohio's Division of Cannabis Control oversees licensing for cultivation, processing, testing, and retail operations. The state imposes a 10 percent excise tax on retail sales. Ohio's existing medical program, launched in 2019, serves approximately 250,000 registered patients with qualifying conditions including cancer, chronic pain, PTSD, and epilepsy. The adult-use market generated approximately $400 million in sales during its first full year of operation in 2024.

Pennsylvania

Pennsylvania operates a medical-only program established by the Medical Marijuana Act, signed by Governor Tom Wolf on April 17, 2016. The program launched in February 2018 and serves approximately 450,000 registered patients with qualifying conditions including cancer, epilepsy, PTSD, autism, and chronic pain. Patients may possess up to a 30-day supply as determined by their certifying physician. Pennsylvania prohibits smokable flower, limiting products to vaporizable oils, tinctures, capsules, and topicals. The state's medical market generated approximately $1.8 billion in sales during 2024. Adult-use legalization bills have been introduced in the state legislature but have not advanced to floor votes.

Market and Business Implications

Trump's cannabis policy shift triggered immediate capital market reactions, with the AdvisorShares Pure US Cannabis ETF gaining 12 percent in the week following The Washington Post report, while analysts project Section 280E elimination could add $2-3 billion in annual EBITDA across the multi-state operator sector. The most immediate financial impact centers on Section 280E tax treatment. Multi-state operators currently report effective tax rates of 70-90 percent due to the prohibition on deducting ordinary business expenses. Curaleaf Holdings reported $1.5 billion in revenue and $180 million in net income during 2024, with tax expenses exceeding $200 million. Rescheduling to Schedule III would allow full deduction of operating expenses, potentially doubling net income for major operators. Green Thumb Industries, Trulieve Cannabis, and Verano Holdings face similar tax burdens, with combined Section 280E impact estimated at $800 million annually across the top four MSOs. Banking access represents a second critical business constraint. Approximately 60 percent of cannabis transactions occur in cash due to financial institution reluctance to serve the sector. The American Bankers Association reports that fewer than 800 of the nation's 4,000 banks and credit unions actively serve cannabis clients, despite FinCEN guidance establishing compliance frameworks. Rescheduling would not eliminate Bank Secrecy Act obligations but could reduce perceived regulatory risk, expanding banking relationships and reducing cash-handling costs estimated at 10-15 percent of revenue for cash-intensive operators. Capital markets access remains constrained by federal prohibition. Major U.S. stock exchanges including Nasdaq and the New York Stock Exchange prohibit listings of companies that violate federal law, forcing cannabis operators to trade on over-the-counter markets or Canadian exchanges. Curaleaf, Green Thumb Industries, Trulieve, Cresco Labs, and other major MSOs trade on the Canadian Securities Exchange or OTCQX, limiting institutional investor participation. Rescheduling to Schedule III would not automatically enable U.S. exchange listings, as cultivation and distribution would remain federally prohibited for non-medical use, but could influence exchange policy decisions. Interstate commerce restrictions limit operational efficiency and market consolidation. The Controlled Substances Act prohibits interstate transportation of Schedule I substances, forcing multi-state operators to maintain separate cultivation and manufacturing operations in each state. This regulatory structure prevents economies of scale, increases capital requirements, and creates supply-demand imbalances. A California cultivation facility cannot ship product to New York during supply shortages. Rescheduling to Schedule III would not eliminate interstate commerce restrictions, as the Controlled Substances Act maintains prohibitions on interstate distribution of Schedule III substances without DEA registration. Full descheduling or congressional action would be required to enable interstate commerce. Wholesale pricing dynamics reflect federal policy uncertainty. Cannabis flower wholesale prices declined from approximately $1,800 per pound in 2020 to $800-1,000 per pound in mature markets like Colorado, Oregon, and California during 2024, driven by oversupply and limited interstate commerce. Rescheduling could accelerate consolidation as improved profitability enables acquisitions, potentially stabilizing pricing through capacity rationalization. However, continued state-level market fragmentation would limit pricing convergence across regions. Intellectual property protection remains limited under federal prohibition. The U.S. Patent and Trademark Office accepts utility patent applications for cannabis-related inventions but denies trademark registrations for products that violate federal law. This creates brand protection challenges for consumer-facing companies investing in product development and marketing. Rescheduling would enable federal trademark registration for medical cannabis products, strengthening brand value and facilitating national expansion strategies.

What Experts Say

Industry analysts, legal scholars, and policy advocates offer divergent assessments of Trump's cannabis policy implications, with consensus that rescheduling represents meaningful but incomplete reform. Cowen analyst Vivien Azer, who covers cannabis equities, stated in a June 2026 research note that rescheduling to Schedule III would represent "the most significant federal cannabis policy development in 50 years" but cautioned that continued prohibition for adult use limits upside for recreational-focused operators. Azer projected that Section 280E elimination could increase EBITDA margins by 15-20 percentage points for profitable operators while doing little to improve economics for unprofitable companies facing structural challenges. Sam Kamin, professor of marijuana law and policy at the University of Denver Sturm College of Law, explained in a February 2025 interview that rescheduling would not resolve the fundamental federal-state conflict. According to Kamin, Schedule III classification maintains federal prohibition for non-medical use, meaning state-licensed adult-use businesses would continue to violate federal law despite improved tax treatment. Kamin argued that congressional action through legislation like the SAFE Banking Act or the MORE Act would be necessary to provide comprehensive legal clarity. Morgan Fox, political director of the National Organization for the Reform of Marijuana Laws, said in a March 2025 statement that the Trump administration's approach represents "incremental progress within a fundamentally flawed framework." According to Fox, rescheduling fails to address criminal justice priorities including expungement of prior convictions, release of individuals incarcerated for cannabis offenses, and elimination of collateral consequences including immigration penalties and public housing restrictions. Kevin Sabet, president of Smart Approaches to Marijuana, argued in a January 2025 op-ed that rescheduling would accelerate commercialization and normalization of cannabis use, increasing public health risks. According to Sabet, the appropriate policy framework would maintain Schedule I classification while expanding access to FDA-approved cannabis medications through traditional pharmaceutical development pathways, similar to Epidiolex, the FDA-approved CBD medication for epilepsy. Kris Krane, president of 4Front Ventures, stated in a cannabis industry conference in April 2025 that Trump's policy approach creates a "best-case scenario within the constraints of executive authority." According to Krane, rescheduling combined with continued state-level legalization momentum positions the industry for congressional action in a second Trump term or subsequent administration.

What's Next

The Trump administration faces multiple decision points through 2026, including finalizing the DEA rescheduling rule, issuing DOJ enforcement guidance, and responding to congressional banking and tax reform legislation. The most immediate decision involves the DEA rescheduling process. The Notice of Proposed Rulemaking published in May 2024 initiated a formal Administrative Procedure Act process requiring public comment periods, administrative law judge hearings, and final rule publication. The DEA received over 43,000 public comments during the initial comment period, with submissions from medical associations, cannabis businesses, advocacy organizations, and individual patients. Administrative law judge hearings were scheduled for December 2025 and January 2026, with testimony from scientific experts, DEA officials, and stakeholders. The DEA must review the administrative record and issue a final rule or withdraw the proposal. Legal challenges are expected regardless of outcome, potentially delaying implementation through 2027. Congressional action represents a parallel pathway. The SAFE Banking Act, which would prohibit federal banking regulators from penalizing financial institutions serving state-legal cannabis businesses, passed the House seven times between 2019 and 2023 but stalled in the Senate. Senate Majority Leader Chuck Schumer introduced the Cannabis Administration and Opportunity Act in 2022, which would deschedule cannabis entirely and establish a federal regulatory framework, but the legislation never received a floor vote. Republican control of both chambers following the 2024 elections creates uncertainty about legislative prospects, with some Republican members supporting banking reform while opposing full legalization. State-level legalization momentum continues independent of federal action. Ballot initiatives for adult-use legalization are expected in multiple states during the 2026 election cycle, including potential measures in Arkansas, Missouri, and South Dakota. Legislative legalization efforts are advancing in states including Pennsylvania, Minnesota, and Wisconsin. Each additional state program increases pressure on federal policymakers to resolve the federal-state conflict. International developments may influence U.S. policy. Germany launched adult-use legalization in April 2024, joining Canada, Uruguay, and Mexico in permitting recreational cannabis. The United Nations Commission on Narcotic Drugs voted in December 2020 to remove cannabis from Schedule IV of the 1961 Single Convention, the most restrictive category, while maintaining Schedule I classification. Further international liberalization could reduce U.S. concerns about treaty compliance. The 2028 presidential election will determine long-term policy direction. If Trump serves a second term through January 2029, his administration would have seven years to implement cannabis policy changes. A Democratic successor would likely continue or accelerate reform efforts, while a Republican successor's approach would depend on the nominee's position. Public opinion polling shows approximately 70 percent of Americans support adult-use legalization, with majority support across most demographic groups, suggesting continued political momentum regardless of administration.

Further Reading

• Controlled Substances Act, 21 U.S.C. § 801 et seq. - https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling, Federal Register Vol. 89, No. 97 (May 16, 2024) - https://www.federalregister.gov/documents/2024/05/16/2024-10633/schedules-of-controlled-substances-rescheduling-of-marijuana
• HHS Recommendation to Reschedule Marijuana (August 2023) - https://www.hhs.gov/about/news/2023/08/30/hhs-recommends-rescheduling-marijuana.html
• Cole Memorandum on Marijuana Enforcement (August 29, 2013) - https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf
• FinCEN Guidance on Marijuana-Related Businesses (February 14, 2014) - https://www.fincen.gov/resources/statutes-regulations/guidance/bsa-expectations-regarding-marijuana-related-businesses
• Internal Revenue Code Section 280E - https://www.law.cornell.edu/uscode/text/26/280E
• National Conference of State Legislatures Cannabis Overview - https://www.ncsl.org/health/cannabis-overview
• Congressional Research Service, "Marijuana: Medical and Retail - Selected Legal Issues" (updated regularly) - https://crsreports.congress.gov
• Marijuana Policy Project State Policy Database - https://www.mpp.org/states/
• NORML State Laws Database - https://norml.org/laws/